Torbay Pharma bolsters leadership team to drive North American growth

14 May 2024

Torbay Pharma, a global leader in the manufacture and distribution of terminally sterilized injectables for the secondary care market, is reinforcing its North American expansion strategy by enlisting top-tier professionals to fortify its senior leadership cadre.

Fueled by a recent investment injection from private equity firm NorthEdge, the contract manufacturer (CMO) and license holder is welcoming Mohammed Nazir (Naz) as Chief Operating Officer (COO) and Tara Slivey as Chief People Officer (CPO). Both Naz and Tara bring with them extensive experience in the pharmaceutical industry, having held executive positions in prominent companies such as Pantheon and Pfizer. Naz will leverage his operational acumen to bolster Torbay Pharma‘s manufacturing growth plans, while Tara’s expertise in people and cultural development, coupled with her background in pharmaceutical manufacturing within private equity-owned enterprises, will prove instrumental in enhancing the company’s organizational dynamics.

Emma Rooth, CEO of Torbay Pharma, emphasized the company’s unwavering commitment to innovation, efficiency, and patient well-being as it expands its footprint in North America. She stated, “As we broaden our presence in North America, we are steadfast in our dedication to innovation, efficiency, and, most importantly, patient care. By augmenting our leadership team, we aim to accelerate our growth trajectory while concurrently collaborating with the FDA to secure regulatory approval.




The timing of Torbay Pharma’s expansion endeavors is particularly pertinent amid the backdrop of supply chain disruptions and escalating demand for essential medications within the US healthcare sector. Many of the products manufactured by Torbay Pharma are already in high demand, underscoring the pivotal role the company plays in addressing critical healthcare needs.

In a significant stride towards its investment goals, Torbay Pharma has successfully completed the initial phase of its packaging automation program, poised to streamline the manufacturing-to-release process substantially. Emma Rooth elaborated on this achievement, stating, “Torbay Pharma is dedicated to enhancing our operational capabilities and service offerings. In addition to the ongoing automation initiatives within our packaging and warehousing departments, we are actively exploring technological advancements to drive efficiency, flexibility, and scalability across our operations.”

Renowned for its specialized expertise in filling generic injectables into both plastic and glass containers, Torbay Pharma has witnessed a surge in demand for its plastic parenteral nutrition (PN) products across the North American landscape over the past two years.

Torbay Pharma’s strategic reinforcement of its leadership team and ongoing investments in operational enhancements underscore its commitment to delivering quality pharmaceutical solutions and driving innovation in the North American market. As the company continues to expand its presence and product offerings, it remains poised to meet the evolving needs of healthcare providers and patients alike.